AstraZeneca Non-Clinical PhD Studentship in Next-generation TPD for Oncology: Harnessing Ubiquitin-independent Pathways
University of Cambridge · United Kingdom
Funded 4-year PhD in the Department of Pharmacology, University of Cambridge, with AstraZeneca. The project develops ubiquitin-independent targeted protein degradation by co-opting Midnolin, combining Midnolin biology with binder discovery and engineered degrader tools for oncology targets. Suits a
Biology & Life Sciences11h ago
